PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC

• E. Lee,
• M. Matasar,
• R. Conlon,
• K. Mody,
• S. Fiset,
• J. Graff

Affiliations

E. Lee

1 Compassionate Cancer Care Group, Fountain Valley

M. Matasar

2 Memorial Sloan Kettering Cancer Center, Montvale, United States of America

R. Conlon

3 IMV inc., Dartmouth

K. Mody

3 IMV inc., Dartmouth

S. Fiset

4 IMV inc., Quebec City, Canada

J. Graff

3 IMV inc., Dartmouth